

Henning Gädeke

Michael Makanga

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d’Or

1060 Brussels

Belgium

Madrid, 6 April 2026

Letter of endorsement

Dear Sir,

On behalf of FUNDACION MUNDO SANO ESPANA (FMS ESPANA), GRAN VIA CARLOS III, 98, 08028 Barcelona, Spain, VAT G-61911335, and in accordance with Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe, I hereby submit this letter of endorsement in support of our role as a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Fundación Mundo Sano España is a non-profit organisation dedicated to improving global health and addressing health inequalities, with a strong focus on poverty-related and neglected diseases. Our mission and operational priorities are fully aligned with the objectives of Global Health EDCTP3 JU, particularly with regard to the implementation, exploitation and scale-up of research results that can generate measurable public health impact in low- and middle-income countries.

Our contribution to Global Health EDCTP3 JU is articulated through our participation in the EDCTP3-funded action Project 101103089 — STOP2030 (“STOP2030: Towards the interruption of transmission of soil-transmitted helminths”), implemented from 1 July 2023 to 30 June 2026. The project aims to accelerate the pathway to impact of an innovative fixed-dose combination (FDC) of co-formulated ivermectin and albendazole by complementing registrational clinical trial data with programmatically relevant evidence to inform policy, WHO guidance and national decision-making.

Within STOP2030, Fundación Mundo Sano España provides a targeted and value-adding contribution to both implementation and exploitation activities. The core clinical component consists of a pragmatic safety and effectiveness trial conducted in collaboration with the Ghana Health Service (GHS) and the Kenya Medical Research Institute (KEMRI), with genomic epidemiology inputs from the Wellcome Sanger Institute. Mundo Sano contributes to this work through medical monitoring activities delivered by a specialised medical team with extensive experience in monitoring clinical research in sub-Saharan Africa. Data generated will directly inform modelling and cost-effectiveness analyses coordinated by KEMRI (WP3) and feed into downstream policy and implementation activities.

In addition, Mundo Sano leads key exploitation and communication activities under Work Package 5, which is designed to support the uptake, sustainability and policy relevance of the project results. Mundo Sano is responsible for Task 5.3, covering both the development (Task 5.3a) and implementation (Task 5.3b) of a Comprehensive Communication and Promotion Plan. This plan is conceived as a flexible and adaptive tool to support the Consortium’s pathway to impact by: (i) positioning the implementation of the FDC on the agenda of sub-Saharan African countries; (ii) strengthening the visibility, credibility and reputation of the STOP2030 Consortium; and (iii) contributing to the visibility of the Global Health EDCTP3 funding programme.

Implementation of the plan includes stakeholder engagement and mapping, development of shared communication tools and visual identity, dissemination of emerging results through specialised media and Consortium channels, targeted capacity-building and communication activities for health personnel and communities, and advocacy actions aimed at informing national and international policy dialogue. These activities are implemented in close coordination with Bridges to Development, Liconsa, KEMRI and GHS, and evolve in parallel with the generation of scientific evidence to maximise efficiency, accelerate timelines and enhance impact.

We estimate the total value of this contribution to be 251,250 euros.

We hereby confirm our full compliance with the Horizon Europe Regulation (EU) No 2021/695, Council Regulation (EU) No 2085/2021, the Horizon Europe Model Grant Agreement and all applicable Global Health EDCTP3 JU rules and work programmes. We also confirm our capacity to deliver the above commitments and our understanding that Global Health EDCTP3 JU will allocate resources based on these commitments.

Yours faithfully,

Madrid, 6 April 2026

Firmado por:

A handwritten signature in black ink that reads "Marina Gold". The signature is written in a cursive, flowing style.

C4B38A85D895484...

Marina Gold

Chief Executive Officer (CEO)

Fundación Mundo Sano España